Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

RoosterBio and Tissue Regeneration Therapeutics Collaborate on Human Umbilical Cord-Derived MSC Bioprocess Systems

June 9, 2019 By Cade Hildreth, Founder & President Leave a Comment

Collaboration commercializes biological tools to advance the companies’ shared goal of accelerating the field of Regenerative Medicine.

FREDERICK, Md., May 29, 2019 — RoosterBio Inc. and Tissue Regeneration Therapeutics Inc.(TRT) today announced a strategic collaboration to advance their shared goal of accelerating the development of the Regenerative Medicine field. This collaboration will productize TRT’s core technology around human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) to the entire Regenerative Medicine marketplace. This powerful set of biological tools will be made commercially available via integration into RoosterBio’s unique product formats for rapid incorporation into tomorrow’s Regenerative Medicine products. [Read more…]

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

June 4, 2019 By Cade Hildreth, Founder & President Leave a Comment

MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]

Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent

May 6, 2019 By Cade Hildreth, Founder & President Leave a Comment

FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]

ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation

April 29, 2019 By Cade Hildreth, Founder & President Leave a Comment

MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]

PBKM (Famicord) May Acquire Esperite NV (Cryo-Save) Stem Cell Banking Business

March 11, 2019 By Cade Hildreth, Founder & President Leave a Comment

Amsterdam, the Netherlands – 22 February 2019 — Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are both leading in the stem cell banking sector. Cryo-Save is one of the largest and longest operating stem cell bank in Europe, in which store more than 330.000 umbilical cord blood samples and tissues. [Read more…]